Nektar lifted by Merck alliance for bempeg, new trial fundin...

Nektar Therapeutics is waiting on multiple data readouts for its lead drug bempegaldesleukin paired with strategic partner Bristol-Myers Squibb’s checkpoint inhibitor Opdivo, but that hasn’

Nektar pulls pain drug after bruising FDA panel meeting

Nektar, BioMarin, and Alnylam top list of biotech M&A target...

With Takeda’s £46 billion acquisition of Shire, it’s been a busy year for pharma M&A – and according to analysts Datamonitor, the specialist biotechs Nektar, BioMarin and Alnylam are th

BMS makes record $1.8bn bet on Nektar cancer drug

Bristol-Myers Squibb scored a first-in-class approval with cancer immunotherapy Opdivo just a few years ago – could it be about repeat the trick with a new drug that stimulates natural kill

BMS and Nektar to pair Opdivo with natural killer cell drug

BMS and Nektar's combination latest in frenzied immunotherapy field